BACKGROUND: A phase 1 trial was used to evaluate a combination of cisplatin, gemcitabine, and escalating doses of veliparib in patients with untreated advanced pancreatic ductal adenocarcinoma (PDAC) in 2 cohorts: a germline BRCA1/2-mutated (BRCA1) cohort and a wild-type BRCA (BRCA-) cohort. The aims were to determine the safety, dose-limiting toxicities (DLTs), maximum tolerated dose, and recommended phase 2 dose (RP2D) of veliparib combined with cisplatin and gemcitabine and to assess the antitumor efficacy (Response Evaluation Criteria in Solid Tumors, version 1.1) and overall survival. METHODS: Gemcitabine and cisplatin were dosed at 600 and 25 mg/m 2 , respectively, over 30 minutes on days 3 and 10 of a 21-day cycle. Four dose levels of veliparib were evaluated: 20 (dose level 0), 40 (dose level 1), and 80 mg (dose level 2) given orally twice daily on days 1 to 12 and 80 mg given twice daily on days 1 to 21 (dose level 2A [DL2A]). RESULTS: Seventeen patients were enrolled: 9 BRCA1 patients, 7 BRCA-patients, and 1 patient with an unknown status. DLTs were reached at DL2A (80 mg twice daily on days 1 to 21). Two of the 5 patients in this cohort (40%) experienced grade 4 neutropenia and thrombocytopenia. Two grade 5 events occurred on protocol. The objective response rate in the BRCA1 cohort was 7 of 9 (77.8%). The median overall survival for BRCA1 patients was 23.3 months (95% confidence interval [CI], 3.8-30.2 months). The median overall survival for BRCA-patients was 11 months (95% CI, 1.5-12.1 months). CONCLUSIONS: The RP2D of veliparib was 80 mg by mouth twice daily on days 1 to 12 in combination with cisplatin and gemcitabine; the DLT was myelosuppression. Substantial antitumor activity was seen in BRCA1 PDAC. A randomized phase 2 trial is currently evaluating cisplatin and gemcitabine with and without veliparib for BRCA1 PDAC (NCT01585805). Cancer 2018;124:1374-82. V C 2018 American Cancer Society.
INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-related mortality worldwide and has an overall 5-year survival rate of 8%. 1 Multi-agent cytotoxic combinations such as 5-fluorouracil, leucovorin, oxaliplatin, irinotecan (FOLFIRINOX) and gemcitabine/nab-paclitaxel have improved the outcomes for advanced PDAC; nonetheless, overall survival for most patients is less than a year. [2] [3] [4] Advances in the identification of genomic alterations, specifically the ability to accurately identify relevant genetic mutations, have ushered in an era of unprecedented precision medicine in oncology in general. In PDAC, germline BRCA2 and BRCA1 mutations, which occur in up to 5% to 7% of patients, lead to an increased risk of developing PDAC, which is estimated to be 2.5-to 3.5-fold higher than the risk for the general population. 5, 6 In addition to the known increased sensitivity to DNA-damaging chemotherapy in women with breast and ovarian cancer, mutations in BRCA genes have generated much attention since the discovery of their synthetically lethal interaction with poly(adenosine diphosphate ribose) polymerase (PARP). 7, 8 PARP is a family of enzymes, and 2 of these enzymes, PARP1 and PARP2, are key components of the DNA-repair mechanism for cells with single-strand DNA breaks and nucleoside base damage. 9 Poly(adenosine diphosphate ribose) polymerase inhibitor (PARPi) therapy has been effective in tumors with defects in homologous recombination such as breast and ovarian cancers with BRCA1 or BRCA2 mutations. 10, 11 In vitro work in a PDAC cell line (BRCA2-mutated Capan-1) demonstrated single-agent activity for the PARPi KU-0058684 and in combination with cytotoxic agents. 12, 13 Clinical trials have demonstrated the viability of exploiting this deficiency in DNA repair in other cancers such as breast cancer, ovarian cancer, and PDAC. 10, 11, 14 Given the rationale for evaluating DNA-damaging agents and PARPi agents in germline BRCA-mutated patients (BRCA1), we designed a series of trials in PDAC. The specific goals were 1) to evaluate the appropriate dose and schedule for combining the PARPi veliparib with cisplatin and gemcitabine and 2) to evaluate the activity of single-agent veliparib in BRCA1 PDAC (with the results reported in a related article) 15 and, on the basis of goal 1, to design a random assignment phase 2 trial to assess the efficacy of cisplatin plus gemcitabine with and without veliparib in advanced BRCA/PALB21 PDAC. Herein we report the phase 1 evaluation of cisplatin, gemcitabine, and veliparib in 2 cohorts of patients with PDAC, one with and one without a germline BRCA1/2 mutation. We specifically chose to evaluate a combination regimen in which the delivery of the PARPi preceded cytotoxic therapy to maximize the potential for synergistic synthetic lethality, and we further chose to evaluate 12-and 21-day continuous-dosing schedules of veliparib because we recognized upfront that myelosuppression was anticipated to be dose-limiting. This study was designed in conjunction with the National Cancer Institute's Cancer Therapeutics and Evaluation Program and the Lustgarten Foundation.
MATERIALS AND METHODS

Study Design and Treatment
This was a single-arm phase 1 study. The primary endpoint was the determination of the maximum tolerated dose (MTD) and the dose-limiting toxicity (DLT) for the combination of veliparib with gemcitabine and cisplatin and the identification of the recommended phase 2 dose (RP2D) for the triplet. The secondary endpoints were the determination of the safety and oncologic outcomes (response rate, progression-free survival, and overall survival) for this combination. This trial was reviewed by the institutional review and privacy boards at all sites. All patients provided written informed consent.
It was estimated that a minimum of 6 patients and a maximum of 24 patients would be studied. Three to 6 patients were treated at each veliparib dose level. Treatment was administered in 21 day cycles, with fixed doses of gemcitabine and cisplatin give on the 3rd and 10th days. Intravenous gemcitabine was dosed at 600 mg/m 2 , and intravenous cisplatin was dosed at 25 mg/m 2 ; both were infused over 30 minutes. Veliparib was given orally twice daily, with the duration of dosing dependent on the dose level of the patient group (Table 1) , and aspartate aminotransferase/alanine aminotransferase levels 2.5 times the institutional ULN (unless there was evidence of liver metastases, in which case the aspartate aminotransferase/ alanine aminotransferase levels had to be 5 times the institutional ULN and the creatinine level had to be 1.5 times the ULN). Females of child-bearing potential required a negative pregnancy test. Patients with a known active infection (eg, hepatitis B/C) and human immunodeficiency virus-positive patients who did not have evidence of significant immunocompromise were eligible. Patients were excluded if they had received prior adjuvant therapy with a platinum drug and if PDAC had recurred within 6 months of adjuvant therapy or if central nervous system metastases were stable for 3 months. Patients who had contraindications to platinum agents or were receiving any other investigational agents were excluded. Patients with a history of seizures or allergic reactions attributed to compounds with a composition similar to that of veliparib or other agents were also excluded. In addition, patients with uncontrolled infections, cardiovascular disease, or psychiatric illness were ineligible.
Patients were removed from the study treatment if they experienced disease progression or intercurrent illness that precluded treatment administration, had unacceptable toxicity, experienced a longer than 2-week delay in initiating cycle 2, or voluntarily chose to change therapy. Up to 3 dose reductions per drug were permitted per patient.
DLT and Biostatistical Design
The primary endpoint was the determination of the MTD, DLT, and RP2D for veliparib combined with cisplatin and gemcitabine. The DLT assessment period applied to the first cycle of treatment (21 days). Toxicities were assessed according to the Common Terminology Criteria for Adverse Events, version 4. Hematologic DLTs included grade 4 (G4) thrombocytopenia or neutropenia, grade 3 (G3) thrombocytopenia with bleeding, and febrile neutropenia (fever > 38.58C and neutrophil count/lL < 0.5). Nonhematologic DLTs included G3 diarrhea, nausea, and vomiting refractory to loperamide or anti-emetic therapy and unable to be corrected to grade 1 or lower within 24 hours. G4 metabolic toxicities (except for hyperglycemia) were DLTs, regardless of their duration.
Dose escalation was conducted via a 3 1 3 design. Three to 6 patients were treated per dose level. If fewer than 1 of 3 patients or fewer than 2 of 6 patients experienced a DLT, the dose was escalated to the next level. If 1 of 3 patients experienced a DLT, the cohort was expanded to 6. This continued until the aforementioned criteria were exceeded. The MTD and the RP2D were 1 dose level below the DLT.
Toxicity was assessed with the Common Terminology Criteria for Adverse Events, version 4.0. Radiologic restaging (RECIST, version 1.1) was conducted every 6 weeks (2 cycles) from the start of therapy with a window period of 65 days. All patients were followed for survival until death.
A number of correlative studies designed to evaluate the presence/absence of a loss of heterozygosity, identification reversion BRCA mutations, and gene expression signatures were also included in this phase 1 trial and will be reported in a separate article.
RESULTS
Patient Characteristics and Treatment
Baseline patient characteristics are shown in Table 1 . Seventeen patients (10 males and 7 females) with a median age of 58 years (range, 41-71 years) were enrolled between February 2012 and October 2013 at 3 sites: the Memorial Sloan Kettering Cancer Center, the Princess Margaret Cancer Centre, and the University of Chicago Medical Center. The cutoff for the data analysis was June 30, 2017. Fifteen patients (88.2%) had stage IV disease, and 2 patients (11.8%) had stage III disease (both BRCA-). Nine patients (52.9%) were BRCA1, and 7 patients (41.2%) were BRCA-. One patient had an undetermined BRCA status and was included in the BRCA-group. Four dose levels were evaluated. DL0, DL1, and DL2 had no DLTs, so a new dose level, DL2A, was added. At DL2A, 2 of 5 patients experienced DLTs. This led to the recommended dose of veliparib for combination therapy with gemcitabine and cisplatin being D2: 80 mg twice daily on days 1 to 12 in combination with fixed doses of cisplatin and gemcitabine.
Toxicities and Dose Reductions
Hematologic toxicities
Hematologic toxicities, as captured during cycle 1 (the DLT assessment period), are shown in Table 2 . During the DLT period, DL0 and DL1/2 were well tolerated. DL2A had 7 G3 events and 6 G4 events. Four of the 6 G4 events were DLTs (neutropenia and thrombocytopenia; n 5 2); both of these patients had dose reductions and continued with the study. Beyond the DLT period, 2 patients experienced G4 neutropenia (DL2), and 3 patients experienced G4 thrombocytopenia (DL2). One patient at DL2A developed febrile neutropenia.
Nonhematologic toxicities and grade 5 events
Nonhematologic toxicities are summarized in Table 3 . There were no dose-limiting nonhematologic toxicities. DL0 had 1 G4 event of elevated bilirubin. At DL2A, there was 1 G4 biliary infection in the context of a known biliary stent; this patient also experienced several other G3 biliary infections during the treatment course.
There were 2 grade 5 events during the study. One patient developed acute myeloid leukemia (AML). This patient was a 60-year-old male with BRCA21 stage IV PDAC who had a family history significant for BRCArelated cancers and AML. The patient had a complete response per RECIST against metastatic PDAC but developed AML 2.5 years into his treatment and died shortly thereafter of AML. A cytogenetic analysis determined that this was likely a therapy-related event, with deletions of 5q31 and 7q31 detected in 66% and 61.3% of cells, respectively. A second patient, a 70-year-old male with BRCA11 stage IV PDAC who had a personal history significant for esophageal perforation and hernia repair, experienced a fatal colonic perforation. An evaluation during the event indicated a malignant stricture versus a diverticular stricture. The event occurred at the end of cycle 3 and may have been related to the therapy response rather than a diverticular stricture. The patient was nonneutropenic at the time.
Dose reductions
Outside the DLT period, 12 patients (70.6%) had reductions in gemcitabine and cisplatin: 9 (75%) because of Hematologic toxicity  G2  G3  G4  G2  G3  G4  G2  G3  G4  G2  G3  G4   Leukopenia  1 The best target response is shown in Figure 1A . For responders, the median time to the best response was 7.4 months (95% confidence interval [CI], 5.1-15.7 months). For the entire cohort of BRCA1 patients (n 5 9), the median best response to treatment was a 66.7% reduction in the total tumor volume (95% CI, 35.2%-76.8%). For BRCA-patients, the median best response was a 1.4% reduction according to RECIST (95% CI, 5.4% increase to 10.6% decrease). Figure 1B shows the overall survival and duration on treatment. The median duration on treatment for the entire cohort was 4.2 months (95% CI, 4-13.8 months). For the BRCA1 patients, the median duration on treatment was 9.7 months (95% CI, 6.4-22 months). For the BRCA-patients, the median duration on treatment was 2.3 months (95% CI, 1-5 months). Figure 2 shows the overall survival of the entire cohort identified by the BRCA status. BRCA1 patients had a median survival of 23.3 months (95% CI, 3.8-30.2 Toxicity  G2  G3  G4  G5  G2  G3  G4  G2  G3  G4  G2  G3  G4   Gastrointestinal  Nausea  2  1  3  1  Diarrhea  2  1  Vomiting  1  2  Metabolic  Hyperglycemia  3  1  2  3  Hypomagnesemia  1  2 months). BRCA-patients had a median survival of 11 months (95% CI, 1.5-12.1 months). One BRCA1 patient remained alive, with recent discontinuation of the protocol therapy (late 2016), after more than 3 years of disease control.
Patient Survival
DISCUSSION
Treatment for advanced PDAC is evolving, and therapy refinement and patient selection are emerging realities in small subsets of patients with this disease. 16 Increasing evidence indicates that germline BRCA1 patients are one such important subgroup. We chose to evaluate in a prospective fashion the utility of platinum-based therapy combined with a PARPi in subgroups of patients with PDAC so that the concept of synthetic lethality could be evaluated and potentially exploited.
The combination of gemcitabine and cisplatin has been evaluated at various doses and schedules in patients with sporadic PDAC; however, no optimal dose and schedule have been confirmed. For the most part, antitumor efficacy has been modest in randomized trials evaluating the addition of cisplatin or oxaliplatin to gemcitabine in comparison with gemcitabine alone in unselected patients. [17] [18] [19] [20] [21] A randomized phase 3 trial with gemcitabine and cisplatin for advanced biliary cancers supported the use of gemcitabine at 1000 mg/m 2 and cisplatin at 25 mg/m 2 on days 1 and 8 every 3 weeks; however, lower doses of gemcitabine have previously been demonstrated to have activity against advanced PDAC.
22, 23 We chose to evaluate a fixed cisplatin dose of 25 mg/m 2 and a fixed gemcitabine dose of 600 mg/m 2 and to dose-escalate veliparib. Although cisplatin plus gemcitabine may have limited activity against PDAC absent a homologous recombination defect, we hypothesized that it would be an effective regimen for BRCA1 patients and for an enriched patient population (surrogate family/personal history of cancer). We chose this dose and schedule to 1) preserve the platinum dose, 2) minimize the myelosuppressive impact of the combination by reducing the gemcitabine dose, 3) permit the addition of the PARPi, and 4) allow a treatment that could be administered for a prolonged period. Despite the lower dose of gemcitabine, the dose intensity of gemcitabine, when calculated, was comparable to that of standard approaches. 23 A key principle underpinning the hypothesis is that a combination strategy would delay the emergence of resistance by overcoming the limitations of a single-agent targeted approach. This trial evaluated 17 patients with advanced PDAC. The RP2D of veliparib for the combination with cisplatin at 25 mg/m 2 and gemcitabine at 600 mg/m 2 is 80 mg twice daily on days 1 to 12 every 21 days. Target inhibition is known to be achieved at this dose level of veliparib. 24 Predictably, hematologic toxicity was doselimiting. Although we could not directly compare the frequency or severity of toxicities between the BRCA1 and BRCA-cohorts because of the unequal distribution of the 2 cohorts by dose level, we subjectively did not appreciate a significant different in toxicity.
A key point of the study was to determine whether an active regimen such as this could be administered longitudinally. Feasibility was met in this regard. One early toxicity with fatal colonic perforation was suspected to have a benign etiology and to be unrelated to therapy. One late event was notable: AML. Myelosuppression is well documented with gemcitabine and cisplatin combinations. 25, 26 Veliparib has been shown to enhance the myelosuppression of cytotoxic agents, and given the patient's extended treatment duration (2.5 years), we speculate that cumulative myelosuppression and exposure to this triplet combination therapy may have led to AML. 27, 28 Furthermore, therapy-related AML is a rare but well documented complication of both PARPi therapy and cytotoxic therapy. 29 In addition, preclinical data have shown that genetic ablation of PARP increases the incidence of cancer, and this suggests a tumor-suppressor function for PARP. 30 This possible role may be more pronounced in patients with prolonged PARP inhibition, such as our Figure 2 . Kaplan-Meier overall survival curves based on the BRCA status. The median survival for BRCA1 patients was 23.3 months (95% confidence interval, 3.8-30.2 months). The median survival for BRCA-patients was 11 months (95% confidence interval, 1.5-12.1 months). One patient who was BRCA1 remained alive after more than 3 years of disease control.
aforementioned patient. Substantial activity for the triplet combination was identified in BRCA1 patients. For the study overall, 7 of 17 patients (41.2%) had a RECIST response; all of these patients were BRCA1. Specifically, for the BRCA1 cohort, the response rate was 7 of 9 (77.8%), and these responses were deep according to RECIST (Fig. 1A) . No BRCA-patients had an objective tumor response. BRCA1 patients had a median overall survival of 23.3 months (95% CI, 3.8-30.2 months), and BRCA-patients had a median overall survival of 11 months (95% CI, 1.5-12.1 months). Figure 1B further supports this therapy's effectiveness in the BRCA1 population. Although the median on-treatment duration for BRCA-patients was 2.3 months (95% CI, 1-5 months), the median on-treatment duration for BRCA1 patients was 9.7 months (95% CI, 6.4-22 months). This 4-fold difference in treatment duration suggests that the response to therapy is both significant and durable in BRCA1 patients. A variety of subsequent therapies were administered after the discontinuation of the protocol therapy. FOLFIRINOX (n 5 3), gemcitabine/nab-paclitaxel (n 5 2), and both regimens (n 5 4) were most common. In addition, 4 patients (23.5%) had a combination of platinum and another agent, and 1 patient (5.9%) received palliative radiation. Three patients (17.6%) received no further cancer-directed therapy.
Although proof-of-concept trials have demonstrated the effectiveness of PARPi agents against breast and ovarian cancers, information regarding their potential in combination therapy against PDAC is limited. 31, 32 Our trial is the first prospective study to evaluate cisplatin-based therapy in a BRCA1 patient population.
We acknowledge the limitations of a small, nonrandomized study with respect to the conclusions drawn. The efficacy data, though limited, clearly support the further development of a synthetic lethality-based therapy for genomically selected PDAC. We further draw the conclusion that a family history in our data set does not appear to be an effective surrogate for predicting the utility of platinum-based therapy or significant enrichment for a BRCA1 status; however, we do recognize that other retrospective data sets suggest that the presence of a family history of cancer may be a surrogate for platinum sensitivity. [33] [34] [35] Our cohort of BRCA-patients had family histories notable for potentially BRCA-related cancers; however, their treatment outcomes (Fig. 1A) and duration on treatment (Fig. 1B) resembled outcomes typical of a sporadic PDAC setting.
Our results do provide prospective, robust evidence for existing preclinical data that suggest the actionability of a BRCA1 status in PDAC. 36 The exact reason for the improvement in outcomes is unclear, with synthetic lethality, platinum, or likely the combination of all 3 drugs being a plausible explanation for the activity along with the potential contribution of other genes involved in the DNA-damage response and PDAC susceptibility (eg, ATM). 37 A randomized phase 2 trial of cisplatin/gemcitabine with and without veliparib is ongoing and will provide more insight into the therapeutic potential of this triplet in patients with BRCA1 PDAC.
In conclusion, the combination of cisplatin, gemcitabine, and veliparib can be safely administered to patients with advanced PDAC. Hematologic toxicity is dose-limiting. Substantial activity can be observed in a genomically selected subgroup of patients with germline BRCA1 PDAC.
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